Jubilant Biosys Expands European Footprint with Pierre Fabre's R&D Centre

Jubilant Biosys, a subsidiary of Jubilant Pharmova, has executed definitive agreements to acquire an 80% stake in Jasmin, a French entity holding Pierre Fabre's R&D Centre at Saint Julien, France. This strategic move enhances Jubilant Biosys' capabilities in biologics and antibody-drug conjugates (ADCs), expanding its European presence. The acquisition, valued at approximately €4.4 million over two years, aims to bolster Jubilant's drug discovery services and tap into a $500 million addressable market in ADCs. Pierre Fabre retains a 20% stake in Jasmin.

 

Source: Jubilant Pharmova, CNBC TV18, Outsourced Pharma